Scholarlink

Background <p>Candidemia is a life-threatening fungal infection in intensive care unit (ICU) patients that can be complicated by secondary localization (SL). However, the prevalence, risk-factors, and outcomes of patients with secondary localization during candidemia remain poorly explored.</p> Methods <p>The CandidICU study was a retrospective multicenter cohort study conducted in 16 French ICUs. All adult patients hospitalized from 01-2015 to 01-2023 for candidemia were enrolled. We assessed the prevalence and risk-factors for SL. In addition, we explored the clinical course according to the screening and occurrence of SL.</p> Results <p>Among 492 patients hospitalized in ICU with at least one positive blood culture for <i>Candida</i> sp., 376 were screened for SL (76.4%). At least one SL was diagnosed in 82 patients (21.8%). Competing risk analysis identified the SAPSII score and the duration of positive blood cultures as independent risk factors for SL (sdHR 1.01 [95%CI 1.00-1.02]; p = 0.031 and sdHR 1.05 [95%CI 1.02−1.08]; p = 0.003, respectively). Age and <i>Candida glabrata</i> infection were protective factors against SL (sdHR 0.98 [95%CI 0.97−1.00]; p = 0.016 and sdHR 0.38 [95%CI 0.15-0.99]; p = 0.048, respectively). Finally, patients with SL received longer antifungal treatment (18 [11−30] versus 14 [6–18] days; p &lt; 0.001) and had a higher rate of antifungal escalation (27.8% versus 12.3%; p = 0.002).</p> Conclusions <p>In this cohort, 76·4% of ICU patients with candidemia were screened for SL and at least one SL was diagnosed in 21·8%. The severity at ICU admission and duration of positive blood cultures were identified as independent risk factors for SL, whereas age and <i>Candida glabrata</i> infection were protective. Finally, the screening and occurrence of SL were associated with significant changes in the management of patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Screening, prevalence, and risk factors for secondary localization during candidemia in intensive care unit patients: the French CandidICU multicenter study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月5日

查看全文
  • Florian Reizine,
  • Juliette Henry,
  • Luc Desmedt,
  • Christophe Camus,
  • Valentin Coirier,
  • François Arrive,
  • Estelle Burban,
  • Gabriel Eustache,
  • Tony Belleville,
  • Antoine Marc,
  • Jolan Malherbe,
  • Pierre Bouju,
  • Paul Jaubert,
  • Olivier Lesieur,
  • Maxime Leclerc,
  • Pierre Fillâtre,
  • Aurélien Frérou,
  • Renaud Prével,
  • Nolwenn Mainguy,
  • Hélène Guegan,
  • Anne Cady,
  • Laurence Delhaes,
  • Sébastien Imbert,
  • Florent Morio,
  • Estelle Perraud,
  • Solène Le Gal,
  • Julie Bonhomme,
  • Marc Pihet,
  • Clarisse Dupin,
  • Damien Du Cheyron,
  • Yoann Launey,
  • Cécile Aubron,
  • Jean-Pierre Gangneux

摘要

Background

Candidemia is a life-threatening fungal infection in intensive care unit (ICU) patients that can be complicated by secondary localization (SL). However, the prevalence, risk-factors, and outcomes of patients with secondary localization during candidemia remain poorly explored.

Methods

The CandidICU study was a retrospective multicenter cohort study conducted in 16 French ICUs. All adult patients hospitalized from 01-2015 to 01-2023 for candidemia were enrolled. We assessed the prevalence and risk-factors for SL. In addition, we explored the clinical course according to the screening and occurrence of SL.

Results

Among 492 patients hospitalized in ICU with at least one positive blood culture for Candida sp., 376 were screened for SL (76.4%). At least one SL was diagnosed in 82 patients (21.8%). Competing risk analysis identified the SAPSII score and the duration of positive blood cultures as independent risk factors for SL (sdHR 1.01 [95%CI 1.00-1.02]; p = 0.031 and sdHR 1.05 [95%CI 1.02−1.08]; p = 0.003, respectively). Age and Candida glabrata infection were protective factors against SL (sdHR 0.98 [95%CI 0.97−1.00]; p = 0.016 and sdHR 0.38 [95%CI 0.15-0.99]; p = 0.048, respectively). Finally, patients with SL received longer antifungal treatment (18 [11−30] versus 14 [6–18] days; p < 0.001) and had a higher rate of antifungal escalation (27.8% versus 12.3%; p = 0.002).

Conclusions

In this cohort, 76·4% of ICU patients with candidemia were screened for SL and at least one SL was diagnosed in 21·8%. The severity at ICU admission and duration of positive blood cultures were identified as independent risk factors for SL, whereas age and Candida glabrata infection were protective. Finally, the screening and occurrence of SL were associated with significant changes in the management of patients.